BelleLipo – Bioactive Solution for Localized Fat Reduction
BelleLipo
BelleLipo peptide® is a targeted peptide solution designed to address localized fat deposits.
Through advanced bioactive action, it helps reshape the body by supporting lipolysis and tissue smoothing.This painless and effective treatment is ideal for professionals offering body-contouring solutions.
KEY BENEFITS
Targets localized fat for body reshaping.
Improves skin firmness in treated areas.
Supports natural lipolytic activity.
Enhances tissue smoothness and contour definition.
SCIENTIFIC FOUNDATION
BelleLipo peptide® employs a peptide complex that promotes lipolysis and improves microcirculation in adipose tissues.
By modulating inflammatory pathways and enhancing extracellular matrix integrity, it reduces localized fat while improving tissue tone.
HOW IT WORKS
Stimulates lipolysis to reduce localized fat deposits.
Enhances microcirculation for better metabolic activity.
Improves extracellular matrix integrity in target zones.
Supports smoother and more defined body contours.
For professionals
BelleLipo peptide® is a sterile solution for localized body contouring, combining adipocytolytic and lipid-handling actives with Contura™ metabolic peptides to support controlled, progressive fat reduction in targeted areas.
Manufactured under the TruActive Sense™ process, it is formulated without preservatives and positioned for clinics that value professional-grade consistency, clear differentiation, and premium presentation.
Ingredients
Main Actives:
Phosphatidylcholine, Sodium Deoxycholate
Contura™ Pentapeptide-52, Pentapeptide-25, Hexapeptide-39, Tripeptide-4
Metabolic Support
Caffeine, L-Carnitine
Indications
BelleLipo peptide® is intended for professional use in adult patients (≥25 years) to support body contour improvement by addressing localized subcutaneous fat after appropriate clinical assessment.
Best candidates (physician-selected):
- Stable weight with discrete, clinically appreciable subcutaneous fat pads on physical examination
- Mild-to-moderate localized adiposity with acceptable skin quality
- Patients seeking targeted contour refinement (not overall weight loss)
Most appropriate clinical presentations
- Localized fat bulges (well-defined pockets): abdomen (upper/lower), flanks/hips, back rolls (bra line), posterior upper arms, inner thighs, inner knees
- Residual localized fat pockets persisting after lifestyle changes, where the primary issue is subcutaneous fat accumulation
- Mild contour asymmetry driven by localized adipose deposits (patient-dependent)
Not indicated / limitations:
- Generalized obesity or visceral/central fat predominance
- Lipedema or predominantly fibrotic disorders where fat is not a typical localized pad
- Cases where the primary concern is skin laxity or cellulite without a measurable fat pad
- Use in the presence of active skin infection/inflammation at the site, known hypersensitivity to any component, pregnancy/lactation (where applicable)
Medical INFO
BelleLipo peptide® is designed for the management of localized subcutaneous adipose tissue through a multi-phase biological process driven by its active profile: adipocyte disruption, lipid emulsification/dispersion, immune-mediated lipid clearance, and metabolic-signaling support to optimize lipid handling in the treated microenvironment.
1. Primary adipocytolytic phase — adipocyte membrane disruption
Deoxycholic acid (as sodium deoxycholate) is a bile-acid–derived, membrane-active agent. In subcutaneous fat, it promotes adipocyte membrane disruption, leading to adipocytolysis and release of intracellular lipid content into the local interstitial space.
Clinical implication: this mechanism is associated with a predictable local inflammatory response that is part of the clearance process.
Primary active responsible: Sodium deoxycholate / Deoxycholic acid.
2. Lipid emulsification & dispersion — physicochemical lipid handling
Following adipocytolysis, released triglycerides and lipid droplets require dispersion to facilitate downstream biological processing. Phosphatidylcholine (a phospholipid) supports lipid emulsification and micellar dispersion, promoting a more homogeneous local lipid phase and supporting subsequent clearance pathways.
Primary active responsible: Phosphatidylcholine.
3. Controlled inflammatory cascade & macrophage-mediated lipid clearance
Adipocytolysis initiates a localized inflammatory cascade with recruitment of immune cells. Macrophages contribute to phagocytosis and clearance of lipid debris, followed by progressive resolution over time. This explains why contour changes develop gradually over weeks rather than immediately.
Primary driver: Deoxycholic acid (adipocytolysis)
Supportive role: Phosphatidylcholine (lipid dispersion supporting processing)
4. Metabolic signaling support — lipid mobilization and utilization pathways
Beyond adipocytolysis and dispersion, BelleLipo peptide® includes co-actives intended to support adipose metabolic signaling and lipid handling:
• Contura™ (Pentapeptide-52, Pentapeptide-25, Acetyl Hexapeptide-39, Tripeptide-41) is positioned as a bioactive peptide signaling system supporting regulatory pathways involved in lipid metabolism in the adipose microenvironment, including signaling associated with lipid mobilization, processing, and metabolic activity (supportive role alongside primary adipocytolysis)
• Caffeine supports cAMP-linked lipolytic signaling and local metabolic activity (supportive role)
• Levocarnitine (L-Carnitine) supports fatty-acid transport into mitochondria, facilitating β-oxidation capacity (supportive role)
Supportive actives: Contura™, Caffeine, Levocarnitine
5. Tissue microenvironment support (adjunct)
Methylsilanol mannuronate is included as a supportive component positioned to contribute to tissue microenvironment quality as localized volume decreases (adjunctive role).
Supportive active: Methylsilanol mannuronate
Formulation rationale (TruActive Sense™)
BelleLipo peptide® follows TruActive Sense™, a preservative-free, minimal-component formulation approach, designed to avoid unnecessary excipients while focusing on functional actives and supportive co-factors.
Physician Summary (Clinical Decision Support)
BelleLipo peptide® may be considered a first-choice option when the objective is localized body contour refinement in patients with:
- Discrete, clinically appreciable subcutaneous fat pads on examination
- Mild-to-moderate localized adiposity (not generalized obesity)
- A contour concern primarily driven by subcutaneous fat rather than skin laxity alone
Why it can be first choice (active-linked rationale)
- Primary fat-reducing driver: Sodium deoxycholate / deoxycholic acid → adipocytolysis via membrane disruption
- Improved lipid handling: Phosphatidylcholine → lipid emulsification & dispersion
- Biological completion: adipocytolysis-triggered inflammation → macrophage-mediated clearance over time
- Metabolic optimization layer: Contura™ + caffeine + levocarnitine → support lipid-metabolism signaling and utilization pathways
- Formulation philosophy: TruActive Sense™ → preservative-free, minimal-component design
Not ideal as first choice when the predominant issue is visceral fat, generalized obesity, or primary skin laxity/cellulite without a measurable fat pad.
BelleLipo peptide® is the regenerative bioactive solution for localized fat reduction. Contact Persebelle to expand your body-contouring treatments.
